Loading
A phase 1/2 trial of Cemiplimab, Tocilizumab in ovarian cancer and endometrial cancer, run by Regeneron Pharmaceuticals, now recruiting.
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers is a phase 1/2 interventional study registered as NCT03564340 by Regeneron Pharmaceuticals, with 890 participants planned, started 2018-05-21 and due to reach its primary completion in 2027-05-10. Interventions recorded: Ubamatamab, Cemiplimab, Sarilumab, Tocilizumab. Conditions listed: Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ubamatamab, Regeneron, Cemiplimab, Endometrial cancer.
Shares Ubamatamab, Regeneron, Cemiplimab, Ovarian cancer.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/